(Q36761523)

English

Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms

scientific article published on January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

decision support system

1 reference

based on heuristic

inferred from title

0 references

1

object named as

Nadia Harbeck

0 references

author name string

Manfred Schmitt

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Stefan Paepke

3

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Heike Allgayer

4

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Ronald E Kates

5

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Critical Reviews in Clinical Laboratory Sciences

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

179-201

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

The plasminogen activation system in tumor growth, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Urokinase receptor: a molecular organizer in cellular communication.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

uPAR: a versatile signalling orchestrator

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

The urokinase-type plasminogen activator system in cancer and other pathological conditions: introduction and perspective

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

New developments in the urokinase-type plasminogen activator system.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Limited Prognostic Value of c-erbB-2 Compared to uPA and PAI-1 in Primary Breast Carcinoma

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Gene expression profiling of breast cancer: a new tumor marker

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Survival analysis and neural nets.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

A neural network model for survival data

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Feed forward neural networks for the analysis of censored survival data: a partial logistic regression approach

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Neural networks and logistic regression: Part I

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Neural networks and logistic regression: Part II

1 reference

https://api.crossref.org/works/10.1080%2F10408360601040970

21 January 2018

Identifiers

10.1080/10408360601040970

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36761523&oldid=1655436204"